EMA approvals

Market Access

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike

Market Access

The FDA released its overview of 2023 and the drugs it had approved during the year.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.